Vladimir Han
Research Subjects
Vladimir Han has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Matej Skorvanek
Department of Neurology University of Pavol Jozef Safarik in Kosice Kosice Slovakia
7 shared publications - Ján Necpál
Department of Neurology Zvolen Hospital Zvolen Slovakia
5 shared publications - Miriam Ostrozovicova
Department of Neurology, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia
4 shared publications - Zuzana Gdovinova
Department of Neurology, Faculty of Medicine (N.L., Z.G.), P.J. Safarik University and L. Pasteur University Hospital, Košice, Slovakia
4 shared publications - Alexandra Lackova
Department of Neurology P.J. Safarik University Kosice Slovak Republic
3 shared publications - Egon Kurča
Neurology Department Jessenius Faculty of Medicine and University Hospital Martin, Martin, Slovakia
3 shared publications
Latest Publications
- Open Access
- 22 March 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (8) , 1132-1139
Prevalence and Clinical Characteristics of the LRRK2 p.L1795F Variant in Central Europeans with Early‐Onset and Familial Parkinson's Disease
Background: Leucine‐rich repeat kinase 2 (LRRK2) p.L1795F variant was proposed as a genetic risk factor for Parkinson's disease (PD). However, its prevalence, phenotype, and origin remain unknown.Objective: The aim was to evaluate the frequency and phenotype of p.L1795F in early‐onset PD (EOPD) and familial PD compared to healthy controls (HC) in Central Europe.Methods: Whole‐exome sequencing was used to screen 219 EOPD and familial PD patients of Central Europeans compared to HC. Sanger sequencing assessed segregation. Detailed clinical phenotype was evaluated for all positive carriers.Results: p.L1795F was identified in 1.37% (3/219) and 3.23% of familial cases (3/93), with no carriers among HCs (0/303). Segregation analysis confirmed association with PD. Carriers were traced to the eastern Slovak–Hungarian region. It also appears to be associated with a more aggressive phenotype.Conclusion: Our data indicate that p.L1795F contributes to PD in Central Europe. Further exploration in larger cohorts is warranted to establish its contribution to global PD risk.
- 22 March 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (8) , 1132-1139
Open AccessPrevalence and Clinical Characteristics of the LRRK2 p.L1795F Variant in Central Europeans with Early‐Onset and Familial Parkinson's Disease
Background: Leucine‐rich repeat kinase 2 (LRRK2) p.L1795F variant was proposed as a genetic risk factor for Parkinson's disease (PD). However, its prevalence, phenotype, and origin remain unknown.Objective: The aim was to evaluate the frequency and phenotype of p.L1795F in early‐onset PD (EOPD) and familial PD compared to healthy controls (HC) in Central Europe.Methods: Whole‐exome sequencing was used to screen 219 EOPD and familial PD patients of Central Europeans compared to HC. Sanger sequencing assessed segregation. Detailed clinical phenotype was evaluated for all positive carriers.Results: p.L1795F was identified in 1.37% (3/219) and 3.23% of familial cases (3/93), with no carriers among HCs (0/303). Segregation analysis confirmed association with PD. Carriers were traced to the eastern Slovak–Hungarian region. It also appears to be associated with a more aggressive phenotype.Conclusion: Our data indicate that p.L1795F contributes to PD in Central Europe. Further exploration in larger cohorts is warranted to establish its contribution to global PD risk.
- Open Access
- 7 December 2023
- Published by Wiley in European Journal of Neurology
- Vol. 31 (4)
Central European Group on Genetics of Movement Disorders
- 7 December 2023
- Published by Wiley in European Journal of Neurology
- Vol. 31 (4)
Open AccessCentral European Group on Genetics of Movement Disorders
- 4 March 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 111, 105352
Predictors of whole exome sequencing in dystonic cerebral palsy and cerebral palsy-like disorders
- 4 March 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 111, 105352
Predictors of whole exome sequencing in dystonic cerebral palsy and cerebral palsy-like disorders
- Open Access
- 29 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1604
Alzheimer’s Disease-Associated SNP rs708727 in SLC41A1 May Increase Risk for Parkinson’s Disease: Report from Enlarged Slovak Study
SLC41A1 (A1) SNPs rs11240569 and rs823156 are associated with altered risk for Parkinson’s disease (PD), predominantly in Asian populations, and rs708727 has been linked to Alzheimer’s disease (AD). In this study, we have examined a potential association of the three aforementioned SNPs and of rs9438393, rs56152218, and rs61822602 (all three lying in the A1 promoter region) with PD in the Slovak population. Out of the six tested SNPs, we have identified only rs708727 as being associated with an increased risk for PD onset in Slovaks. The minor allele (A) in rs708727 is associated with PD in dominant and completely over-dominant genetic models (ORD = 1.36 (1.05–1.77), p = 0.02, and ORCOD = 1.34 (1.04–1.72), p = 0.02). Furthermore, the genotypic triplet GG(rs708727) + AG(rs823156) + CC(rs61822602) might be clinically relevant despite showing a medium (h ≥ 0.5) size difference (h = 0.522) between the PD and the control populations. RandomForest modeling has identified the power of the tested SNPs for discriminating between PD-patients and the controls to be essentially zero. The identified association of rs708727 with PD in the Slovak population leads us to hypothesize that this A1 polymorphism, which is involved in the epigenetic regulation of the expression of the AD-linked gene PM20D1, is also involved in the pathoetiology of PD (or universally in neurodegeneration) through the same or similar mechanism as in AD.
- 29 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1604
Open AccessAlzheimer’s Disease-Associated SNP rs708727 in SLC41A1 May Increase Risk for Parkinson’s Disease: Report from Enlarged Slovak Study
SLC41A1 (A1) SNPs rs11240569 and rs823156 are associated with altered risk for Parkinson’s disease (PD), predominantly in Asian populations, and rs708727 has been linked to Alzheimer’s disease (AD). In this study, we have examined a potential association of the three aforementioned SNPs and of rs9438393, rs56152218, and rs61822602 (all three lying in the A1 promoter region) with PD in the Slovak population. Out of the six tested SNPs, we have identified only rs708727 as being associated with an increased risk for PD onset in Slovaks. The minor allele (A) in rs708727 is associated with PD in dominant and completely over-dominant genetic models (ORD = 1.36 (1.05–1.77), p = 0.02, and ORCOD = 1.34 (1.04–1.72), p = 0.02). Furthermore, the genotypic triplet GG(rs708727) + AG(rs823156) + CC(rs61822602) might be clinically relevant despite showing a medium (h ≥ 0.5) size difference (h = 0.522) between the PD and the control populations. RandomForest modeling has identified the power of the tested SNPs for discriminating between PD-patients and the controls to be essentially zero. The identified association of rs708727 with PD in the Slovak population leads us to hypothesize that this A1 polymorphism, which is involved in the epigenetic regulation of the expression of the AD-linked gene PM20D1, is also involved in the pathoetiology of PD (or universally in neurodegeneration) through the same or similar mechanism as in AD.
- Open Access
- 24 January 2022
- Published by Hindawi Limited in Parkinson's Disease
- Vol. 2022, 1-8
Prevalence of Fabry Disease among Patients with Parkinson’s Disease
Background. An increased prevalence of Parkinsons disease (PD) disease has been previously reported in subjects with Fabry disease (FD) carrying alpha-galactosidase (GLA) mutations and their first-line relatives. Moreover, decreased alpha-galactosidase A (AGLA) enzymatic activity has been reported among cases with PD compared to controls. Objective. The aim of our study was to determine the prevalence of FD among patients with PD. Methods. We recruited 236 consecutive patients with PD from February 2018 to December 2020. Clinical and sociodemographic data, including the MDS-UPDRS-III scores and HY stage (the Hoehn and Yahr scale), were collected, and in-depth phenotyping was performed in subjects with identified GLA variants. A multistep approach, including standard determination of AGLA activity and LysoGb3 in males, and next-generation based GLA sequencing in all females and males with abnormal AGLA levels was performed in a routine diagnostic setting. Results. The mean age of our patients was 68.9±8.9 years, 130 were men (55.1), and the mean disease duration was 7.77±5.35 years. Among 130 men, AGLA levels were low in 20 patients (15), and subsequent Lyso-Gb3 testing showed values within the reference range for all tested subjects. In 126 subsequently genetically tested patients, four heterozygous p.(Asp313Tyr) GLA variants (3.2, MAF 0.016) were identified; all were females. None of the 4 GLA variant carriers identified had any clinical manifestation suggestive of FD. Conclusions. The results of this study suggest a possible relationship between FD and PD in a small proportion of cases. Nevertheless, the GLA variant found in our cohort is classified as a variant of unknown significance. Therefore, its pathogenic causative role in the context of PD needs further elucidation, and these findings should be interpreted with caution.
- 24 January 2022
- Published by Hindawi Limited in Parkinson's Disease
- Vol. 2022, 1-8
Open AccessPrevalence of Fabry Disease among Patients with Parkinson’s Disease
Background. An increased prevalence of Parkinsons disease (PD) disease has been previously reported in subjects with Fabry disease (FD) carrying alpha-galactosidase (GLA) mutations and their first-line relatives. Moreover, decreased alpha-galactosidase A (AGLA) enzymatic activity has been reported among cases with PD compared to controls. Objective. The aim of our study was to determine the prevalence of FD among patients with PD. Methods. We recruited 236 consecutive patients with PD from February 2018 to December 2020. Clinical and sociodemographic data, including the MDS-UPDRS-III scores and HY stage (the Hoehn and Yahr scale), were collected, and in-depth phenotyping was performed in subjects with identified GLA variants. A multistep approach, including standard determination of AGLA activity and LysoGb3 in males, and next-generation based GLA sequencing in all females and males with abnormal AGLA levels was performed in a routine diagnostic setting. Results. The mean age of our patients was 68.9±8.9 years, 130 were men (55.1), and the mean disease duration was 7.77±5.35 years. Among 130 men, AGLA levels were low in 20 patients (15), and subsequent Lyso-Gb3 testing showed values within the reference range for all tested subjects. In 126 subsequently genetically tested patients, four heterozygous p.(Asp313Tyr) GLA variants (3.2, MAF 0.016) were identified; all were females. None of the 4 GLA variant carriers identified had any clinical manifestation suggestive of FD. Conclusions. The results of this study suggest a possible relationship between FD and PD in a small proportion of cases. Nevertheless, the GLA variant found in our cohort is classified as a variant of unknown significance. Therefore, its pathogenic causative role in the context of PD needs further elucidation, and these findings should be interpreted with caution.
- Open Access
- 5 May 2021
- Published by Wiley in Movement Disorders
- Vol. 36 (8) , 1959-1964
Scoring Algorithm‐Based Genomic Testing in Dystonia: A Prospective Validation Study
Background: Despite the established value of genomic testing strategies, practice guidelines for their use do not exist in many indications.Objectives: We sought to validate a recently introduced scoring algorithm for dystonia, predicting the diagnostic utility of whole‐exome sequencing (WES) based on individual phenotypic aspects (age‐at‐onset, body distribution, presenting comorbidity).Methods: We prospectively enrolled a set of 209 dystonia‐affected families and obtained summary scores (0–5 points) according to the algorithm. Singleton (N = 146), duo (N = 11), and trio (N = 52) WES data were generated to identify genetic diagnoses.Results: Diagnostic yield was highest (51%) among individuals with a summary score of 5, corresponding to a manifestation of early‐onset segmental or generalized dystonia with coexisting non‐movement disorder‐related neurological symptoms. Sensitivity and specificity at the previously suggested threshold for implementation of WES (3 points) was 96% and 52%, with area under the curve of 0.81.Conclusions: The algorithm is a useful predictive tool and could be integrated into dystonia routine diagnostic protocols. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society
- 5 May 2021
- Published by Wiley in Movement Disorders
- Vol. 36 (8) , 1959-1964
Open AccessScoring Algorithm‐Based Genomic Testing in Dystonia: A Prospective Validation Study
Background: Despite the established value of genomic testing strategies, practice guidelines for their use do not exist in many indications.Objectives: We sought to validate a recently introduced scoring algorithm for dystonia, predicting the diagnostic utility of whole‐exome sequencing (WES) based on individual phenotypic aspects (age‐at‐onset, body distribution, presenting comorbidity).Methods: We prospectively enrolled a set of 209 dystonia‐affected families and obtained summary scores (0–5 points) according to the algorithm. Singleton (N = 146), duo (N = 11), and trio (N = 52) WES data were generated to identify genetic diagnoses.Results: Diagnostic yield was highest (51%) among individuals with a summary score of 5, corresponding to a manifestation of early‐onset segmental or generalized dystonia with coexisting non‐movement disorder‐related neurological symptoms. Sensitivity and specificity at the previously suggested threshold for implementation of WES (3 points) was 96% and 52%, with area under the curve of 0.81.Conclusions: The algorithm is a useful predictive tool and could be integrated into dystonia routine diagnostic protocols. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society
- 1 February 2021
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 83, 54-55
Atypical presentations of DYT1 dystonia with acute craniocervical onset
- 1 February 2021
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 83, 54-55
Atypical presentations of DYT1 dystonia with acute craniocervical onset
- 24 June 2020
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 142 (6) , 613-622
Prevalence of non‐motor symptoms and their association with quality of life in cervical dystonia
Objectives Non‐motor symptoms (NMS) are commonly present along with motor impairment in patients with cervical dystonia (CD) and have a significant impact on health‐related quality of life (HRQoL). However, the prevalence of NMS and their association with dystonia are still unclear. The aim of our study was to assess the prevalence of depression, anxiety, fatigue, apathy, pain, sleep problems, and excessive daytime sleepiness (EDS) in CD using different evaluation approaches and to explore their association with HRQoL relative to that of motor symptoms. Materials and Methods We enrolled 102 Slovak patients with CD. The severity of both motor and non‐motor symptoms was assessed using validated scales. HRQoL was determined by the 36‐item Short Form Health Survey (SF‐36). Association of NMS with poor HRQoL was assessed using multiple regressions. Results The most frequent NMS in our sample were sleep impairment (67.3%), anxiety (65.5%), general and physical fatigue (57.5% and 52.9%, respectively), depression (47.1%), mental fatigue (31.4%), apathy (30.4%), reduced activity (29.4%), EDS (20.2%), and reduced motivation (18.6%). Univariate analysis showed that NMS, but not motor symptoms, were significantly linked to poor HRQoL, with EDS being most commonly associated with poor HRQoL, followed by disrupted sleep, depression, and fatigue. Conclusions The prevalence of NMS among patients with CD is high, and some NMS are strongly associated with poor HRQoL, while motor impairment was not associated with the severity of NMS or poor HRQoL. Actively diagnosing and treating NMS should therefore be a routine part of the clinical management of patients with CD.
- 24 June 2020
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 142 (6) , 613-622
Prevalence of non‐motor symptoms and their association with quality of life in cervical dystonia
Objectives Non‐motor symptoms (NMS) are commonly present along with motor impairment in patients with cervical dystonia (CD) and have a significant impact on health‐related quality of life (HRQoL). However, the prevalence of NMS and their association with dystonia are still unclear. The aim of our study was to assess the prevalence of depression, anxiety, fatigue, apathy, pain, sleep problems, and excessive daytime sleepiness (EDS) in CD using different evaluation approaches and to explore their association with HRQoL relative to that of motor symptoms. Materials and Methods We enrolled 102 Slovak patients with CD. The severity of both motor and non‐motor symptoms was assessed using validated scales. HRQoL was determined by the 36‐item Short Form Health Survey (SF‐36). Association of NMS with poor HRQoL was assessed using multiple regressions. Results The most frequent NMS in our sample were sleep impairment (67.3%), anxiety (65.5%), general and physical fatigue (57.5% and 52.9%, respectively), depression (47.1%), mental fatigue (31.4%), apathy (30.4%), reduced activity (29.4%), EDS (20.2%), and reduced motivation (18.6%). Univariate analysis showed that NMS, but not motor symptoms, were significantly linked to poor HRQoL, with EDS being most commonly associated with poor HRQoL, followed by disrupted sleep, depression, and fatigue. Conclusions The prevalence of NMS among patients with CD is high, and some NMS are strongly associated with poor HRQoL, while motor impairment was not associated with the severity of NMS or poor HRQoL. Actively diagnosing and treating NMS should therefore be a routine part of the clinical management of patients with CD.